- A recent revision to India's National List of Essential Medicines (NLEM) is expected to lead to savings of between 10 percent to 20 percent for patients on widely used antibiotics, anti-infectives, cardiac and respiratory medicines, The Times of India reported.
- The newspaper suggested that the update will lead to a loss of around Rs 600 crore for companies, with Cipla, Pfizer, Sun Pharmaceutical, Zydus and Lupin to be among those impacted the most.
- In terms of therapies, anti-infectives will be the largest segment in terms of savings for patients, followed by cardiac, neuro and respiratory medicines.
- The new list will be operational with immediate effect once the National Pharmaceutical Pricing Authority fixes their prices.
To read more NewsPoints articles, click here.
